FLORHAM PARK, N.J. - BeyondSpring Inc. (NASDAQ: BYSI), a global clinical-stage biopharmaceutical company, has announced its return to compliance with Nasdaq's minimum bid price requirement.
The company received a notification from the Nasdaq Stock Market on Monday, February 20, 2024, confirming that its ordinary shares' closing bid price had been at or above $1.00 for 10 consecutive business days from February 5 to February 16, 2024.
This development closes the bid price deficiency issue that BeyondSpring had previously disclosed. In addition, BeyondSpring has met the periodic filing requirement set by Nasdaq Listing Rule 5250(c)(2), having filed its Form 6-K for the period ended June 30, 2023, on February 2, 2024. This resolves the filing delinquency matter that was also previously disclosed.
BeyondSpring is focused on developing therapies for patients with significant unmet medical needs. The company's leading asset, Plinabulin, is being advanced as both a direct anti-cancer agent in various cancer indications and as a treatment to prevent chemotherapy-induced neutropenia. BeyondSpring's pipeline also includes three preclinical immuno-oncology assets.
The company's subsidiary, SEED Therapeutics, is utilizing a proprietary targeted protein degradation (TPD) drug discovery platform and has initiated a research and development collaboration with Eli Lilly (NYSE:LLY).
This information is based on a press release statement from BeyondSpring Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.